1. Sung, H, Ferlay, J, Siegel, RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. . 2021;71(3):209-249. doi:
10.3322/caac.21660 Google Scholar |
Crossref |
Medline2. Hooi, JKY, Lai, WY, Ng, WK, et al. Global prevalence of helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153(2):420-429. doi:
10.1053/j.gastro.2017.04.022 Google Scholar |
Crossref |
Medline3. Correa, P, Piazuelo, MB. The gastric precancerous cascade. J Dig Dis. 2012;13(1):2-9. doi:
10.1111/j.1751-2980.2011.00550.x Google Scholar |
Crossref |
Medline4. Koemans, WJ, Luijten, J, van der Kaaij, RT, et al. The metastatic pattern of intestinal and diffuse type gastric carcinoma - A Dutch national cohort study. Cancer Epidemiol. 2020;69:101846. doi:
10.1016/j.canep.2020.101846 Google Scholar |
Crossref |
Medline5. Sarriugarte Lasarte, A, Garcia Alberdi, E, Martinez Indart, L, et al. From Lauren's Diffuse gastric cancer to WHO's Poorly cohesive carcinoma. Clinicopathological and prognostic characteristics. Rev Esp Enferm Dig. 2021;113(5):324-331. doi:
10.17235/reed.2020.7184/2020 Google Scholar |
Medline6. Chen, YC, Fang, WL, Wang, RF, et al. Clinicopathological variation of Lauren classification in gastric cancer. Pathol Oncol Res. 2016;22(1):197-202. doi:
10.1007/s12253-015-9996-6 Google Scholar |
Crossref |
Medline7. Nie, RC, Yuan, SQ, Li, YF, et al. Clinicopathological characteristics and prognostic value of signet ring cells in gastric carcinoma: a meta-analysis. J Cancer. 2017;8(17):3396-3404. doi:
10.7150/jca.21017 Google Scholar |
Crossref |
Medline8. Zhao, S, Lv, L, Zheng, K, Tian, Y, Zheng, JC, Jiang, CG. Prognosis and biological behavior of gastric signet-ring cell carcinoma better or worse: a meta-analysis. Front Oncol. 2021;11:603070. doi:
10.3389/fonc.2021.603070 Google Scholar |
Crossref |
Medline9. Piessen, G, Messager, M, Leteurtre, E, Jean-Pierre, T, Mariette, C. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Ann Surg. 2009;250(6):878-887. doi:
10.1097/SLA.0b013e3181b21c7b Google Scholar |
Crossref |
Medline10. Ribeiro, MM, Sarmento, JA, Sobrinho Simoes, MA, Bastos, J. Prognostic significance of Lauren and Ming classifications and other pathologic parameters in gastric carcinoma. Cancer. 1981;47(4):780-784. doi:
10.1002/1097-0142(19810215)47:4<780::aid-cncr2820470424>3.0.co;2-g.
Google Scholar |
Crossref |
Medline11. Jeong, SH, Park, M, Park, SY, et al. Transcriptome analysis and the prognostic role of NUDC in diffuse and intestinal gastric cancer. Technol Cancer Res Treat. 2021;20:15330338211019501. doi:
10.1177/15330338211019501 Google Scholar |
SAGE Journals |
ISI12. Andjelkovic, M, Alessi, DR, Meier, R, et al. Role of translocation in the activation and function of protein kinase B. J Biol Chem. 1997;272(50):31515-31524. doi:
10.1074/jbc.272.50.31515 Google Scholar |
Crossref |
Medline |
ISI13. Franke, TF, Kaplan, DR, Cantley, LC, Toker, A. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science. 1997;275(5300):665-668. doi:
10.1126/science.275.5300.665 Google Scholar |
Crossref |
Medline14. Gao, T, Furnari, F, Newton, AC. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Molecular Cell. 2005;18(1):13-24. doi:
10.1016/j.molcel.2005.03.008 Google Scholar |
Crossref |
Medline15. Brognard, J, Sierecki, E, Gao, T, Newton, AC. PHLPP And a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Molecular Cell. 2007;25(6):917-931. doi:
10.1016/j.molcel.2007.02.017 Google Scholar |
Crossref |
Medline16. Gao, T, Brognard, J, Newton, AC. The phosphatase PHLPP controls the cellular levels of protein kinase C. J Biol Chem. 2008;283(10):6300-6311. doi:
10.1074/jbc.M707319200 Google Scholar |
Crossref |
Medline17. Liu, J, Weiss, HL, Rychahou, P, Jackson, LN, Evers, BM, Gao, T. Loss of PHLPP expression in colon cancer: role in proliferation and tumorigenesis. Oncogene. 2009;28(7):994-1004. doi:
10.1038/onc.2008.450 Google Scholar |
Crossref |
Medline18. Chen, M, Pratt, CP, Zeeman, ME, et al. Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression. Cancer Cell. 2011;20(2):173-186. doi:
10.1016/j.ccr.2011.07.013 Google Scholar |
Crossref |
Medline19. Molina, JR, Agarwal, NK, Morales, FC, et al. PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma. Oncogene. 2012;31(10):1264-1274. doi:
10.1038/onc.2011.324 Google Scholar |
Crossref |
Medline20. Nitsche, C, Edderkaoui, M, Moore, RM, et al. The phosphatase PHLPP1 regulates Akt2, promotes pancreatic cancer cell death, and inhibits tumor formation. Gastroenterology. 2012;142(2):377-387 e1-5. doi:
10.1053/j.gastro.2011.10.026 Google Scholar |
Crossref |
Medline21. Li, X, Stevens, PD, Liu, J, et al. PHLPP Is a negative regulator of RAF1, which reduces colorectal cancer cell motility and prevents tumor progression in mice. Gastroenterology. 2014;146(5):1301-1312.e1-10. doi:
10.1053/j.gastro.2014.02.003 Google Scholar |
Crossref |
Medline22. Dong, L, Jin, L, Tseng, HY, et al. Oncogenic suppression of PHLPP1 in human melanoma. Oncogene. 2014;33(39):4756-4766. doi:
10.1038/onc.2013.420 Google Scholar |
Crossref |
Medline23. von Elm, E, Altman, DG, Egger, M, Pocock, SJ, Gøtzsche, PC, Vandenbroucke, JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Internal Med. 2007;147(8):573-577. doi:
10.7326/0003-4819-147-8-200710160-00010 Google Scholar |
Crossref |
Medline |
ISI24. Brognard, J, Newton, AC. PHLiPPing the switch on Akt and protein kinase C signaling. Trends Endocrinol Metab. 2008;19(6):223-230. doi:
10.1016/j.tem.2008.04.001 Google Scholar |
Crossref |
Medline25. Yu, Y, Dai, M, Lu, A, Yu, E, Merlino, G. PHLPP1 Mediates melanoma metastasis suppression through repressing AKT2 activation. Oncogene. 2018;37(17):2225-2236. doi:
10.1038/s41388-017-0061-7 Google Scholar |
Crossref |
Medline26. Miyamoto, S, Purcell, NH, Smith, JM, et al. PHLPP-1 negatively regulates Akt activity and survival in the heart. Circ Res. 2010;107(4):476-484. doi:
10.1161/CIRCRESAHA.109.215020 Google Scholar |
Crossref |
Medline27. Wang, Z, Shu, H, Wang, Z, et al. Loss expression of PHLPP1 correlates with lymph node metastasis and exhibits a poor prognosis in patients with gastric cancer. J Surg Oncol. 2013;108(7):427-432. doi:
10.1002/jso.23419 Google Scholar |
Crossref |
Medline28. Hou, Y, Deng, J, Zhang, L, et al. Lower expression of PH domain leucine-rich repeat protein phosphatase 1 (PHLPP1) association with poor prognosis of gastric cancer. Int J Clin Exp Med. 2015;8(11):20481-9.
Google Scholar |
Medline29. Pereira, J, Santos, M, Delabio, R, et al. Analysis of gene expression of miRNA-106b-5p and TRAIL in the apoptosis pathway in gastric cancer. Genes (Basel). 2020;11(4), 393. doi:
10.3390/genes11040393 Google Scholar |
Crossref30. Xu, C, Xie, J, Liu, Y, et al. MicroRNA expression profiling and target gene analysis in gastric cancer. Medicine (Baltimore). 2020;99(37):e21963. doi:
10.1097/md.0000000000021963 Google Scholar |
Crossref |
Medline31. Zhu, X, Liu, Y, Xu, J, et al. miR-608 rs4919510 polymorphism may affect susceptibility to colorectal cancer by upregulating MRPL43 expression. DNA Cell Biol. 2020;39(11):2017-2027. doi:
10.1089/dna.2020.5689 Google Scholar |
Crossref |
Medline
Comments (0)